Perriman Damien Alan 4

What Happened

• Damien Alan Perriman, Chief Commercial Officer of Exozymes, received two awards on April 1, 2026: 62,759 restricted shares (report code A) and 146,437 derivative shares reported as an award (likely stock options), both acquired at $0. These are compensation grants, not open-market purchases or sales, and no cash changed hands at grant.
• The filing reports the awards value as $0 at grant price. The derivative award represents option-type securities subject to vesting; it was not an exercise that produced shares for immediate sale.

Key Details

• Transaction date: 2026-04-01; Filing date (Form 4): 2026-04-08 (filed late relative to the 2-business-day rule).
• Prices: $0.00 per share for both the restricted-stock award (62,759) and the derivative award (146,437).
• Shares owned after transaction: Not specified in this Form 4.
• Footnotes / vesting specifics:
  • F1 (restricted stock): vests at 3,923 shares per quarter, with 15,689 shares vesting immediately; final installment of 3,917 shares on April 1, 2029. Grant and vesting under Rule 16b-3.
  • F2 (option-like grant): vests at 3,050 shares per month, with 36,609 shares vesting immediately; final installment of 3,078 shares on April 1, 2029. Grant and each exercise under Rule 16b-3.
• Filing timeliness: The Form 4 was submitted 7 days after the transaction (filed April 8 for an April 1 grant), which is later than the usual 2-business-day filing requirement for Form 4.

Context

• These awards are standard compensation grants for an executive and do not represent open-market buying or selling. They vest over multiple periods, so they do not necessarily indicate immediate insider selling or additional ownership beyond the vesting schedule.
• The derivative award appears to be an option grant (vests over time); it was not exercised here, so no immediate taxable sale or cashless exercise occurred.